HR Positive/HER2 Low Breast CancerPhase 2NCT06340230
SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer
A Phase 2 study testing SHR-A1811 Injection + Adebrelimab Injection and SHR-A1811 Injection in people with HR Positive/HER2 Low Breast Cancer, run by Shengjing Hospital at 1 site in China.
Trial summary
This is an open-label, phase II study evaluating the efficacy and safety of SHR-A1811 alone or in combination with Adebrelimab in Stage II-III HR Positive/HER2 Low Breast Cancer. Read more about this study
- Who is it for?
- Ages 18 to 75 years, women only
- Conditions the study is for
- HR Positive/HER2 Low Breast Cancer
- What is being tested?
- SHR-A1811 Injection + Adebrelimab Injection and SHR-A1811 Injection
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 93 participants
- Where
- 1 siteChina
- Study dates
- 23 Aug 2024to 28 Feb 2031
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Female patients aged ≥ 18 but ≤ 75 years
- Histologically confirmed to be HR+/HER2-Low invasive breast cancer
- Treatment-naive patients with stage II-III
- Eastern Cooperative Oncology Group (ECOG) score is 0 or 1
- Good level of organ function
- Subjects must participate voluntarily, sign the informed consent form, have good compliance, and cooperate with follow-up visits
Who cannot join
- Previously been treated with any anti-tumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.)
- Received any other anti-tumor therapy at the same time
- Bilateral breast cancer, inflammatory breast cancer or occult breast cancer
- Stage IV breast cancer
- Not confirmed by histopathology
- With a history of any malignancies in the past 5 years, excluding cured cervical carcinoma in situ and melanoma skin cancer
Show all 14Show fewer
- Participated in other drug clinical trials within 4 weeks before enrollment
- Known allergic history of the drug components of this protocol
- History of immunodeficiency
- Clinically significant cardiovascular diseases
- Known or suspected interstitial lung disease
- Active hepatitis and liver cirrhosis
- Known hereditary or acquired bleeding thrombotic tendency
- History of neurological or psychiatric disorders
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Shengjing Hospital affiliated to China Medical University
Shenyang, Liaoning, 110004
Nan Niu, MD, +8618940256668, niunannancy@163.com
Caigang Liu, MD
About this study
Official title: A Phase II Study of SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer
This is an open-label, phase II study evaluating the efficacy and safety of SHR-A1811 alone or in combination with Adebrelimab in Stage II-III HR Positive/HER2 Low Breast Cancer. Subjects will receive the neoadjuvant therapy of SHR-A1811 alone or in combination with Adebrelimab for six cycles, and then undergo surgery within 4 weeks after neoadjuvant therapy. Efficacy will be assessed every 2 cycles.
- Conditions
- HR Positive/HER2 Low Breast Cancer
- Being tested
- SHR-A1811 Injection + Adebrelimab Injection, SHR-A1811 Injection
- Keywords
- SHR-A1811, Adebrelimab, Neoadjuvant, HR Positive/HER2 Low Breast Cancer
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SHR-A1811 Injection + Adebrelimab InjectionDrug
Drug: SHR-A1811 Injection Drug: Adebrelimab Injection
SHR-A1811 Injection + Adebrelimab InjectionDrug
Drug: SHR-A1811 Injection Drug: Adebrelimab Injection
SHR-A1811 InjectionDrug
Drug: SHR-A1811 Injection
| Study group | Role | What they receive |
|---|---|---|
| Arm 1 (PD-L1 Positive) SHR-A1811 Injection + Adebrelimab Injection | Experimental | SHR-A1811 Injection + Adebrelimab Injection Drug: SHR-A1811 Injection Drug: Adebrelimab Injection Receives: Drug: SHR-A1811 Injection + Adebrelimab Injection |
| Arm 2 (PD-L1 Negative) SHR-A1811 Injection + Adebrelimab Injection | Experimental | SHR-A1811 Injection + Adebrelimab Injection Drug: SHR-A1811 Injection Drug: Adebrelimab Injection Receives: Drug: SHR-A1811 Injection + Adebrelimab Injection |
| Arm 3 SHR-A1811 Injection | Experimental | SHR-A1811 Injection Drug: SHR-A1811 Injection Receives: Drug: SHR-A1811 Injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total pathological complete response (tpCR: ypT0-is/ypN0)
Measured: At the time of surgery
Secondary outcomes (8)
Breast pathological complete response (bpCR：ypT0-is)
Measured: At the time of surgery
Residual cancer burden (RCB)
Measured: At the time of surgery
Best overall response rate (BORR)
Measured: During 18 weeks of the neoadjuvant treatment
Overall survival (OS)
Measured: 5 years
Disease-free survival (DFS)
Measured: 5 years
Event-free survival (EFS)
Measured: 5 years
Health-related quality of life (HRQOL) (EORTC QLQ-C30)
The European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) Core 30 (EORTC QLQ-C30)
Measured: During 18 weeks of the neoadjuvant treatment
Health-related quality of life (HRQOL)
The European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire Breast Cancer (EORTC QLQ- BR23) will be used to measure the HRQOL
Measured: During 18 weeks of the neoadjuvant treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Apr 2024
- Study start23 Aug 2024
- Primary completion28 Feb 2026 (estimated)
- Study completion28 Feb 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HR Positive/HER2 Low Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 93 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shengjing Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Jiangsu HengRui Medicine Co., Ltd.
- Responsible party
- Principal investigator, Caigang Liu, Shengjing Hospital
- Investigators
- Caigang Liu, MD, Principal investigator, Shengjing Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06340230
- Sponsor's protocol ID
- BC-NEO-IIT-SHR-A1811-SHR1316
- Status last verified
- Dec 2024
- First submitted
- 25 Mar 2024
- Last updated
- 4 Dec 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase II Study of SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer
- ClinicalTrials.gov ID
- NCT06340230
- Acronym / sponsor ID
- BC-NEO-IIT-SHR-A1811-SHR1316
- Conditions
- HR Positive/HER2 Low Breast Cancer
- Keywords
- SHR-A1811, Adebrelimab, Neoadjuvant, HR Positive/HER2 Low Breast Cancer
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 93 participants (estimated)
- Lead sponsor
- Shengjing HospitalUniversity, hospital or other
- Collaborators
- Jiangsu HengRui Medicine Co., Ltd.
- Study start
- 23 Aug 2024 (actual)
- Primary completion
- 28 Feb 2026 (estimated)
- Study completion
- 28 Feb 2031 (estimated)
- First posted
- 1 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an open-label, phase II study evaluating the efficacy and safety of SHR-A1811 alone or in combination with Adebrelimab in Stage II-III HR Positive/HER2 Low Breast Cancer. Subjects will receive the neoadjuvant therapy of SHR-A1811 alone or in combination with Adebrelimab for six cycles, and then undergo surgery within 4 weeks after neoadjuvant therapy. Efficacy will be assessed every 2 cycles.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Arm 1 (PD-L1 Positive) SHR-A1811 Injection + Adebrelimab Injection | Experimental | Drug: SHR-A1811 Injection + Adebrelimab InjectionSHR-A1811 Injection + Adebrelimab Injection Drug: SHR-A1811 Injection Drug: Adebrelimab Injection |
| Arm 2 (PD-L1 Negative) SHR-A1811 Injection + Adebrelimab Injection | Experimental | Drug: SHR-A1811 Injection + Adebrelimab InjectionSHR-A1811 Injection + Adebrelimab Injection Drug: SHR-A1811 Injection Drug: Adebrelimab Injection |
| Arm 3 SHR-A1811 Injection | Experimental | Drug: SHR-A1811 InjectionSHR-A1811 Injection Drug: SHR-A1811 Injection |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Female patients aged ≥ 18 but ≤ 75 years
- Histologically confirmed to be HR+/HER2-Low invasive breast cancer
- Treatment-naive patients with stage II-III
- Eastern Cooperative Oncology Group (ECOG) score is 0 or 1
- Good level of organ function
Key exclusion criteria (14 listed)
- Previously been treated with any anti-tumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.)
- Received any other anti-tumor therapy at the same time
- Bilateral breast cancer, inflammatory breast cancer or occult breast cancer
- Stage IV breast cancer
- Not confirmed by histopathology
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SHR-A1811 Injection + Adebrelimab InjectionDrug: SHR-A1811 Injection Drug: Adebrelimab Injection | Drug | Arm 1 (PD-L1 Positive) SHR-A1811 Injection + Adebrelimab Injection |
| SHR-A1811 Injection + Adebrelimab InjectionDrug: SHR-A1811 Injection Drug: Adebrelimab Injection | Drug | Arm 2 (PD-L1 Negative) SHR-A1811 Injection + Adebrelimab Injection |
| SHR-A1811 InjectionDrug: SHR-A1811 Injection | Drug | Arm 3 SHR-A1811 Injection |
Primary outcome
Total pathological complete response (tpCR: ypT0-is/ypN0)
Time frame: At the time of surgery
8 secondary outcomes
Breast pathological complete response (bpCR：ypT0-is)
Time frame: At the time of surgery
Residual cancer burden (RCB)
Time frame: At the time of surgery
Best overall response rate (BORR)
Time frame: During 18 weeks of the neoadjuvant treatment
Overall survival (OS)
Time frame: 5 years
Disease-free survival (DFS)
Time frame: 5 years
Event-free survival (EFS)
Time frame: 5 years
Health-related quality of life (HRQOL) (EORTC QLQ-C30)
Time frame: During 18 weeks of the neoadjuvant treatment
Health-related quality of life (HRQOL)
Time frame: During 18 weeks of the neoadjuvant treatment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Dec 2024.
Related trials for HR Positive/HER2 Low Breast Cancer
RecruitingPhase 1
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
PIK3CA Mutations, Advanced Solid Tumors, Adult
RecruitingPhase 2
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
Locally Advanced or Metastatic Breast Cancer
RecruitingPhase 2
A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer
Metastatic Breast Cancer
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Breast Neoplasms, Triple Negative Breast Neoplasms
RecruitingPhase 1/2
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
Hormone Receptor Positive, HER2-low or HER2-ultralow
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Caigang Liu, MD principal investigator
Shengjing Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing SHR-A1811 Injection + Adebrelimab Injection and SHR-A1811 Injection in people with HR Positive/HER2 Low Breast Cancer, run by Shengjing Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Nan Niu, MD (86-18940256668, niunannancy@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total pathological complete response (tpCR: ypT0-is/ypN0) (time frame: At the time of surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Dec 2024.